SCHEMBL6364987

SCHEMBL6364987

OCc1nc(-c2ccc(-c3ccccc3)cc2)nn1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CYP1A2 P05177 2/20 0.47
POLB P06746 2/20 0.46
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
NOTUM Q6P988 1/20 0.43
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14736709 0.80 HDAC1 (0.53) SMN1; SMN2NOTUMHDAC1HDAC6
SCHEMBL6365626 0.77 KMT2A (0.53) KMT2ANPC1RAB9AHPGDSMN1; SMN2
SCHEMBL19231228 0.72 ADORA3 (0.47) HDAC1HDAC6
SCHEMBL14736465 0.72 PDE10A (0.47) KMT2ANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6365513 0.70 KMT2A (0.59) KMT2ANPC1RAB9AHPGDSMN1; SMN2
SCHEMBL14118598 0.69 HDAC1 (0.45) HDAC1HDAC6
SCHEMBL11763001 0.69 NOTUM (0.54) KMT2ANPC1RAB9AHPGDSMN1; SMN2
SCHEMBL13899117 0.68 TDP2 (0.51) NPC1RAB9AALDH1A1LMNA
SCHEMBL2035500 0.67 NR1H3 (0.58) KMT2ANPC1RAB9ASMN1; SMN2NOTUM
SCHEMBL20426104 0.67 ABCG2 (0.55) KMT2ANPC1RAB9ACYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050272784-A1 Inhibitors of bacterial Type III protein secretion systems LI XIAOBING 2005-12-08 US disclosed
WO-2005113522-A1 AZOLE CARBOXAMIDE INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272784-A1 Inhibitors of bacterial Type III protein secretion systems GBA3, PSMB3, SEC61B KMT2A 4719/4885NPC1 2243/4885RAB9A 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.